Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
- Resource Type
- article
- Source
- Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-2 (2023)
- Subject
Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 1756-8722